Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refralon vs Amiodarone for Cardioversion in Paroxysmal AF/AFL
NCT05445297Phase 4Completed
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of niferidil in Atrial fibrillation (AFib) and atrial flutter (AFL). Primary endpoint: Restoration of sinus rhythm at 1 hour. Started Jan 2022; status: completed.
02
Drugs
niferidil
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT05445297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445297.